Literature DB >> 8115269

Aneurysmal change of the ductus arteriosus after prostaglandin E1 administration for pulmonary atresia: demonstration with magnetic resonance imaging.

S Tsubata1, I Hashimoto, F Ichida, A Miyazaki, T Okada, A Murakami, H Morita, K Fukahara.   

Abstract

We report a case of pulmonary atresia in which the ductus arteriosus underwent aneurysmal dilatation after infusion of prostaglandin E1 incorporated in lipid microspheres. To our knowledge this is the first case in which this rare morphological change has been demonstrated with the noninvasive method of magnetic resonance imaging.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8115269     DOI： 10.1007/bf00797003

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN： 0172-0643            Impact factor:   1.655


  8 in total

1.  Cortical hyperostosis following long-term administration of prostaglandin E1 in infants with cyanotic congenital heart disease.

Authors:  K Ueda; A Saito; H Nakano; M Aoshima; M Yokota; R Muraoka; T Iwaya
Journal:  J Pediatr       Date:  1980-11       Impact factor: 4.406

2.  Long-term low-dose prostaglandin E1 administration.

Authors:  P Pitlick; J W French; A Maze; K J Kimble; R L Ariagno; B A Reitz
Journal:  J Pediatr       Date:  1980-02       Impact factor: 4.406

3.  Prostaglandin E1 infants with ductus arteriosus-dependent congenital heart disease.

Authors:  M D Freed; M A Heymann; A B Lewis; S L Roehl; R C Kensey
Journal:  Circulation       Date:  1981-11       Impact factor: 29.690

4.  Long-term prostaglandin E1 therapy in congenital heart defects.

Authors:  O H Teixeira; B Carpenter; S B MacMurray; P Vlad
Journal:  J Am Coll Cardiol       Date:  1984-03       Impact factor: 24.094

5.  The morphology of the human newborn ductus arteriosus: a reappraisal of its structure and closure with special reference to prostaglandin E1 therapy.

Authors:  M M Silver; R M Freedom; M D Silver; P M Olley
Journal:  Hum Pathol       Date:  1981-12       Impact factor: 3.466

6.  Side effects of therapy with prostaglandin E1 in infants with critical congenital heart disease.

Authors:  A B Lewis; M D Freed; M A Heymann; S L Roehl; R C Kensey
Journal:  Circulation       Date:  1981-11       Impact factor: 29.690

7.  Modified Blalock-Taussig shunt following long-term administration of prostaglandin E1 for ductus-dependent neonates with cyanotic congenital heart disease.

Authors:  M Yokota; R Muraoka; M Aoshima; S Nomoto; Y Shiraishi; I Kyoku; M Kitano; I Shimada; H Nakano; K Ueda
Journal:  J Thorac Cardiovasc Surg       Date:  1985-09       Impact factor: 5.209

8.  Prolonged prostaglandin E1 infusion: histologic effects on the patent ductus arteriosus.

Authors:  R B Cole; S Abman; K U Aziz; S Bharati; M Lev
Journal:  Pediatrics       Date:  1981-06       Impact factor: 7.124
  8 in total
  1 in total

Review 1.  PROSTAGLANDINS IN CONGENITAL HEART DISEASE.

Authors:  M Sharma; M Sasikumar; S D Karloopia; B N Shahi
Journal:  Med J Armed Forces India       Date:  2011-07-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.